2014 NICE:心房颤动管理临床指南( CG180)

2014-06-19 NICE



2014 NICE:心房颤动管理临床指南( CG180)


NICE guidelines [CG180] Atrial fibrillation: the management of atrial fibrillation





2014年6月19日,《BMJ》杂志发表了NICE房颤管理指南2014版本,是对2006年指南的更新。NICE基于现有的最佳证据对指南进行了更新,提出了推荐意见,特别是对一些不确定和争议问题。This guideline updates and replaces 'Atrial fibrillation' (NICE clinical guideline 36).Atrial fibrillation is the most common sustained cardiac arrhythmia, and estimates suggest its prevalence is increasing. If left untreated atrial fibrillation is a significant risk factor for stroke and other morbidities. Men are more commonly affected than women and the prevalence increases with age.The aim of treatment is to prevent complications, particularly stroke, and alleviate symptoms. Drug treatments include anticoagulants to reduce the risk of stroke and antiarrhythmics to restore or maintain the normal heart rhythm or to slow the heart rate in people who remain in atrial fibrillation. Non‑pharmacological management includes electrical cardioversion, which may be used to 'shock' the heart back to its normal rhythm, and catheter or surgical ablation to create lesions to stop the abnormal electrical impulses that cause atrial fibrillation.This updated guideline addresses several clinical areas in which new evidence has become available, including stroke and bleeding risk stratification, the role of new antithrombotic agents and ablation strategies.The recommendations apply to adults (18years or older) with atrial fibrillation, including paroxysmal (recurrent), persistent and permanent atrial fibrillation, and atrial flutter. They do not apply to people with congenital heart disease precipitating atrial fibrillation.